The U.S. Food and Drug Administration has approved a drug developed at Stanford Medicine that offers hope to people diagnosed ...

Among important regulatory news last week, US drugmaker BridgeBio Pharma gained Food and Drug Administration (FDA) approval ...

See the new treatment that will break a Pfizer monopoly on a drug for heart disease.

BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for ...

Attruby will be available at a recommended dose of 712 mg, taken twice daily, at a list price of $18,759.12 for a 28-day ...

BBIO gets a significant boost with the FDA approval of acoramidis for the treatment of adults with transthyretin amyloidosis cardiomyopathy. Stock rises.

We project BridgeBio's key drug candidate, Attruby (acoramidis), could achieve global sales of around $3.3 billion by 2033. Attruby is an oral drug designed to treat transthyretin amyloid ...

The Food and Drug Administration (FDA) has approved Attruby TM (acoramidis) for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to ...

With approval, acoramaidis (Attruby; BridgeBio Pharma) becomes the first agent with a label specifying near-complete ...

The FDA has approved Attruby, a new oral treatment that helps reduce heart-related deaths and hospital visits among adults ...